Peter Gottlieb
 
																	
																		 Concepts  (594)
																	
																		
																	 
																	
																		Concepts are derived automatically from a person's publications.  
																	
																	
																			
																					
    Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
     | Name | 
              Number of Publications
             | 
              Most Recent Publication
             | 
              Publications by All Authors
             | 
              Concept Score
             | 
              Why?
             | 
|---|
 | Diabetes Mellitus, Type 1 | 143  | 2025  | 3708  | 6.780  | 
                  Why?
                 |  | Insulin | 52  | 2025  | 2398  | 2.680  | 
                  Why?
                 |  | C-Peptide | 32  | 2025  | 163  | 2.120  | 
                  Why?
                 |  | Islets of Langerhans | 24  | 2025  | 803  | 1.880  | 
                  Why?
                 |  | Autoantibodies | 38  | 2025  | 1501  | 1.700  | 
                  Why?
                 |  | Insulin-Secreting Cells | 18  | 2021  | 372  | 1.600  | 
                  Why?
                 |  | Hypoglycemic Agents | 21  | 2024  | 1285  | 1.480  | 
                  Why?
                 |  | B-Lymphocytes | 10  | 2025  | 847  | 1.180  | 
                  Why?
                 |  | Antilymphocyte Serum | 8  | 2021  | 64  | 1.000  | 
                  Why?
                 |  | T-Lymphocytes | 25  | 2025  | 1999  | 1.000  | 
                  Why?
                 |  | CD4-Positive T-Lymphocytes | 14  | 2025  | 1092  | 0.980  | 
                  Why?
                 |  | Autoantigens | 15  | 2021  | 429  | 0.960  | 
                  Why?
                 |  | Monitoring, Ambulatory | 4  | 2010  | 87  | 0.950  | 
                  Why?
                 |  | Blood Glucose | 17  | 2025  | 2183  | 0.930  | 
                  Why?
                 |  | Autoimmunity | 19  | 2023  | 907  | 0.900  | 
                  Why?
                 |  | Antibodies, Monoclonal, Humanized | 12  | 2023  | 807  | 0.830  | 
                  Why?
                 |  | Proinsulin | 7  | 2024  | 52  | 0.800  | 
                  Why?
                 |  | Clinical Trials as Topic | 12  | 2025  | 1047  | 0.780  | 
                  Why?
                 |  | Immunosuppressive Agents | 9  | 2023  | 891  | 0.770  | 
                  Why?
                 |  | Blood Glucose Self-Monitoring | 4  | 2010  | 640  | 0.680  | 
                  Why?
                 |  | Adolescent | 75  | 2025  | 21555  | 0.670  | 
                  Why?
                 |  | Addison Disease | 8  | 2012  | 43  | 0.670  | 
                  Why?
                 |  | Humans | 163  | 2025  | 137514  | 0.640  | 
                  Why?
                 |  | Adult | 91  | 2025  | 37821  | 0.640  | 
                  Why?
                 |  | CD4 Antigens | 2  | 2013  | 141  | 0.640  | 
                  Why?
                 |  | Immunologic Factors | 7  | 2019  | 239  | 0.640  | 
                  Why?
                 |  | Child | 68  | 2025  | 22037  | 0.610  | 
                  Why?
                 |  | Preventive Medicine | 2  | 2018  | 43  | 0.610  | 
                  Why?
                 |  | Polyendocrinopathies, Autoimmune | 3  | 2010  | 18  | 0.600  | 
                  Why?
                 |  | Prediabetic State | 7  | 2018  | 252  | 0.590  | 
                  Why?
                 |  | Diabetes Mellitus, Type 2 | 6  | 2020  | 2521  | 0.580  | 
                  Why?
                 |  | Young Adult | 48  | 2025  | 13243  | 0.560  | 
                  Why?
                 |  | Peptide Fragments | 13  | 2024  | 708  | 0.560  | 
                  Why?
                 |  | Insulin Antibodies | 6  | 2022  | 105  | 0.550  | 
                  Why?
                 |  | Granulocyte Colony-Stimulating Factor | 6  | 2021  | 74  | 0.530  | 
                  Why?
                 |  | CD8-Positive T-Lymphocytes | 10  | 2019  | 917  | 0.530  | 
                  Why?
                 |  | HLA-DQ Antigens | 11  | 2019  | 181  | 0.520  | 
                  Why?
                 |  | Immunotherapy | 5  | 2024  | 647  | 0.510  | 
                  Why?
                 |  | Mycophenolic Acid | 3  | 2012  | 117  | 0.490  | 
                  Why?
                 |  | Chromogranin A | 2  | 2024  | 42  | 0.470  | 
                  Why?
                 |  | Autoimmune Diseases | 10  | 2017  | 459  | 0.460  | 
                  Why?
                 |  | Peptides | 5  | 2024  | 986  | 0.460  | 
                  Why?
                 |  | Steroid 21-Hydroxylase | 5  | 2012  | 30  | 0.460  | 
                  Why?
                 |  | Monocytes | 4  | 2016  | 568  | 0.460  | 
                  Why?
                 |  | Female | 93  | 2025  | 73162  | 0.460  | 
                  Why?
                 |  | Male | 85  | 2025  | 67718  | 0.450  | 
                  Why?
                 |  | Immunoglobulin G | 6  | 2018  | 886  | 0.450  | 
                  Why?
                 |  | Glutamate Decarboxylase | 9  | 2022  | 170  | 0.450  | 
                  Why?
                 |  | Mice, Inbred NOD | 16  | 2023  | 601  | 0.440  | 
                  Why?
                 |  | Biomarkers | 13  | 2024  | 4172  | 0.430  | 
                  Why?
                 |  | Cytokines | 9  | 2018  | 2095  | 0.430  | 
                  Why?
                 |  | Vaccines, DNA | 1  | 2013  | 32  | 0.420  | 
                  Why?
                 |  | Cystic Fibrosis | 3  | 2012  | 1105  | 0.410  | 
                  Why?
                 |  | Interferon-gamma | 6  | 2021  | 790  | 0.400  | 
                  Why?
                 |  | Myeloid Cells | 1  | 2014  | 146  | 0.400  | 
                  Why?
                 |  | alpha 1-Antitrypsin | 1  | 2014  | 108  | 0.400  | 
                  Why?
                 |  | Immunomodulation | 1  | 2013  | 98  | 0.390  | 
                  Why?
                 |  | T-Lymphocyte Subsets | 8  | 2018  | 425  | 0.390  | 
                  Why?
                 |  | Immunologic Memory | 7  | 2019  | 369  | 0.390  | 
                  Why?
                 |  | Hypoglycemia | 6  | 2009  | 443  | 0.370  | 
                  Why?
                 |  | Disease Progression | 16  | 2021  | 2755  | 0.360  | 
                  Why?
                 |  | Dendritic Cells | 2  | 2014  | 488  | 0.360  | 
                  Why?
                 |  | Anti-Inflammatory Agents, Non-Steroidal | 1  | 2014  | 350  | 0.350  | 
                  Why?
                 |  | Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 4  | 2021  | 63  | 0.340  | 
                  Why?
                 |  | Diabetes Mellitus | 2  | 2023  | 1035  | 0.330  | 
                  Why?
                 |  | Histocompatibility Antigens Class I | 6  | 2011  | 203  | 0.320  | 
                  Why?
                 |  | CD3 Complex | 5  | 2019  | 106  | 0.320  | 
                  Why?
                 |  | Immunoconjugates | 4  | 2014  | 116  | 0.320  | 
                  Why?
                 |  | HLA-DR3 Antigen | 5  | 2022  | 80  | 0.310  | 
                  Why?
                 |  | HLA-DR Antigens | 8  | 2018  | 228  | 0.310  | 
                  Why?
                 |  | Area Under Curve | 9  | 2024  | 316  | 0.310  | 
                  Why?
                 |  | Lymphocyte Activation | 7  | 2025  | 1150  | 0.310  | 
                  Why?
                 |  | Clonal Anergy | 3  | 2018  | 52  | 0.290  | 
                  Why?
                 |  | Insulin, Regular, Human | 3  | 2024  | 43  | 0.280  | 
                  Why?
                 |  | Antibodies, Monoclonal | 5  | 2010  | 1428  | 0.280  | 
                  Why?
                 |  | Hearing Aids | 2  | 2021  | 81  | 0.280  | 
                  Why?
                 |  | Cation Transport Proteins | 3  | 2017  | 134  | 0.270  | 
                  Why?
                 |  | Toll-Like Receptors | 3  | 2014  | 186  | 0.270  | 
                  Why?
                 |  | Age of Onset | 6  | 2020  | 522  | 0.260  | 
                  Why?
                 |  | Tympanic Membrane | 2  | 2017  | 25  | 0.250  | 
                  Why?
                 |  | Zinc Transporter 8 | 4  | 2021  | 87  | 0.250  | 
                  Why?
                 |  | Double-Blind Method | 12  | 2021  | 1987  | 0.250  | 
                  Why?
                 |  | Receptors, Interleukin-2 | 2  | 2006  | 66  | 0.250  | 
                  Why?
                 |  | Time Factors | 10  | 2020  | 6817  | 0.250  | 
                  Why?
                 |  | Regeneration | 2  | 2017  | 195  | 0.250  | 
                  Why?
                 |  | Animals | 33  | 2024  | 37011  | 0.240  | 
                  Why?
                 |  | Glucose Tolerance Test | 6  | 2025  | 361  | 0.230  | 
                  Why?
                 |  | Protein Precursors | 3  | 2016  | 132  | 0.230  | 
                  Why?
                 |  | Genetic Predisposition to Disease | 10  | 2025  | 2420  | 0.230  | 
                  Why?
                 |  | Middle Aged | 36  | 2025  | 33355  | 0.230  | 
                  Why?
                 |  | Insulin, Isophane | 1  | 2004  | 21  | 0.230  | 
                  Why?
                 |  | Antigen Presentation | 3  | 2018  | 216  | 0.230  | 
                  Why?
                 |  | Child, Preschool | 21  | 2025  | 11097  | 0.220  | 
                  Why?
                 |  | T-Lymphocytes, Regulatory | 6  | 2023  | 392  | 0.220  | 
                  Why?
                 |  | Software | 2  | 2008  | 670  | 0.220  | 
                  Why?
                 |  | Mice | 25  | 2024  | 17843  | 0.210  | 
                  Why?
                 |  | Precision Medicine | 3  | 2023  | 426  | 0.210  | 
                  Why?
                 |  | Antibodies, Monoclonal, Murine-Derived | 3  | 2013  | 88  | 0.210  | 
                  Why?
                 |  | Temporal Bone | 2  | 2021  | 52  | 0.210  | 
                  Why?
                 |  | Pregnancy in Diabetics | 2  | 2003  | 123  | 0.210  | 
                  Why?
                 |  | Immunotherapy, Active | 2  | 2014  | 9  | 0.200  | 
                  Why?
                 |  | Diabetic Ketoacidosis | 2  | 2024  | 202  | 0.200  | 
                  Why?
                 |  | Plasmids | 3  | 2013  | 363  | 0.200  | 
                  Why?
                 |  | Histocompatibility Testing | 4  | 2013  | 126  | 0.200  | 
                  Why?
                 |  | Polyethylene Glycols | 3  | 2018  | 640  | 0.190  | 
                  Why?
                 |  | Interleukin-1beta | 3  | 2014  | 373  | 0.190  | 
                  Why?
                 |  | Islets of Langerhans Transplantation | 2  | 2015  | 64  | 0.190  | 
                  Why?
                 |  | Epitopes, T-Lymphocyte | 4  | 2011  | 187  | 0.190  | 
                  Why?
                 |  | Treatment Outcome | 12  | 2024  | 10821  | 0.190  | 
                  Why?
                 |  | Lymphocyte Depletion | 2  | 2013  | 135  | 0.190  | 
                  Why?
                 |  | Body Weight | 2  | 2025  | 973  | 0.190  | 
                  Why?
                 |  | Haplotypes | 6  | 2022  | 491  | 0.190  | 
                  Why?
                 |  | Immune Tolerance | 2  | 2017  | 362  | 0.190  | 
                  Why?
                 |  | Methyldopa | 2  | 2019  | 7  | 0.190  | 
                  Why?
                 |  | Recombinant Fusion Proteins | 2  | 2015  | 665  | 0.180  | 
                  Why?
                 |  | Round Window, Ear | 1  | 2021  | 17  | 0.180  | 
                  Why?
                 |  | Imatinib Mesylate | 1  | 2021  | 79  | 0.180  | 
                  Why?
                 |  | Receptors, Antigen, T-Cell | 5  | 2022  | 720  | 0.180  | 
                  Why?
                 |  | Necrobiosis Lipoidica | 1  | 2001  | 2  | 0.180  | 
                  Why?
                 |  | Hyperglycemia | 1  | 2024  | 346  | 0.180  | 
                  Why?
                 |  | Asymptomatic Diseases | 1  | 2021  | 87  | 0.170  | 
                  Why?
                 |  | Histocompatibility Antigens Class II | 3  | 2011  | 368  | 0.170  | 
                  Why?
                 |  | Platelet-Derived Growth Factor | 1  | 2001  | 91  | 0.170  | 
                  Why?
                 |  | Dose-Response Relationship, Drug | 5  | 2019  | 2066  | 0.170  | 
                  Why?
                 |  | History, 21st Century | 2  | 2018  | 211  | 0.170  | 
                  Why?
                 |  | Administration, Oral | 2  | 2024  | 814  | 0.170  | 
                  Why?
                 |  | History, 20th Century | 2  | 2018  | 324  | 0.170  | 
                  Why?
                 |  | Biomarkers, Pharmacological | 1  | 2020  | 28  | 0.160  | 
                  Why?
                 |  | Interleukin-7 Receptor alpha Subunit | 1  | 2019  | 12  | 0.160  | 
                  Why?
                 |  | Biological Variation, Population | 1  | 2019  | 22  | 0.160  | 
                  Why?
                 |  | Cytomegalovirus | 2  | 2018  | 160  | 0.160  | 
                  Why?
                 |  | Acoustic Stimulation | 1  | 2021  | 344  | 0.160  | 
                  Why?
                 |  | Glucagon-Like Peptides | 1  | 2020  | 56  | 0.160  | 
                  Why?
                 |  | Hepatitis Delta Virus | 3  | 1994  | 7  | 0.160  | 
                  Why?
                 |  | Luminescence | 2  | 2016  | 38  | 0.160  | 
                  Why?
                 |  | Polymorphism, Single Nucleotide | 3  | 2025  | 2193  | 0.160  | 
                  Why?
                 |  | Graves Disease | 2  | 2017  | 34  | 0.160  | 
                  Why?
                 |  | Epitopes | 5  | 2024  | 481  | 0.160  | 
                  Why?
                 |  | Th2 Cells | 2  | 2014  | 176  | 0.160  | 
                  Why?
                 |  | Forkhead Transcription Factors | 3  | 2016  | 191  | 0.150  | 
                  Why?
                 |  | Mass Screening | 2  | 2025  | 1264  | 0.150  | 
                  Why?
                 |  | Gastrointestinal Microbiome | 2  | 2018  | 696  | 0.150  | 
                  Why?
                 |  | Randomized Controlled Trials as Topic | 6  | 2025  | 1465  | 0.150  | 
                  Why?
                 |  | Family | 3  | 2025  | 667  | 0.150  | 
                  Why?
                 |  | Cytoprotection | 1  | 2018  | 56  | 0.150  | 
                  Why?
                 |  | Viral Proteins | 3  | 1997  | 346  | 0.150  | 
                  Why?
                 |  | Immunity, Cellular | 2  | 2018  | 268  | 0.140  | 
                  Why?
                 |  | Thyroiditis, Autoimmune | 1  | 2017  | 15  | 0.140  | 
                  Why?
                 |  | Biomedical Research | 2  | 2018  | 689  | 0.140  | 
                  Why?
                 |  | Diabetes Mellitus, Experimental | 2  | 1990  | 194  | 0.140  | 
                  Why?
                 |  | HLA-A2 Antigen | 1  | 2017  | 48  | 0.140  | 
                  Why?
                 |  | Hearing Loss | 1  | 2021  | 223  | 0.140  | 
                  Why?
                 |  | Twins, Dizygotic | 1  | 2018  | 183  | 0.140  | 
                  Why?
                 |  | Abatacept | 5  | 2023  | 53  | 0.140  | 
                  Why?
                 |  | HLA-DR4 Antigen | 4  | 2022  | 78  | 0.140  | 
                  Why?
                 |  | Twins, Monozygotic | 1  | 2018  | 213  | 0.140  | 
                  Why?
                 |  | Thyroid Gland | 1  | 2017  | 94  | 0.140  | 
                  Why?
                 |  | Antibody-Producing Cells | 1  | 2017  | 30  | 0.140  | 
                  Why?
                 |  | Inflammation | 4  | 2018  | 2837  | 0.140  | 
                  Why?
                 |  | Treatment Failure | 1  | 2018  | 353  | 0.140  | 
                  Why?
                 |  | Heparin-binding EGF-like Growth Factor | 1  | 2017  | 16  | 0.140  | 
                  Why?
                 |  | Magnetic Fields | 1  | 2017  | 24  | 0.130  | 
                  Why?
                 |  | Tympanic Membrane Perforation | 1  | 2017  | 17  | 0.130  | 
                  Why?
                 |  | Th1 Cells | 2  | 2009  | 143  | 0.130  | 
                  Why?
                 |  | Cell Separation | 2  | 2017  | 320  | 0.130  | 
                  Why?
                 |  | Cytomegalovirus Infections | 1  | 2018  | 194  | 0.130  | 
                  Why?
                 |  | Dysbiosis | 1  | 2018  | 180  | 0.130  | 
                  Why?
                 |  | Antibody Formation | 1  | 2018  | 299  | 0.130  | 
                  Why?
                 |  | Influenza, Human | 1  | 2022  | 632  | 0.130  | 
                  Why?
                 |  | Trans-Activators | 1  | 1998  | 399  | 0.130  | 
                  Why?
                 |  | Follow-Up Studies | 8  | 2021  | 5139  | 0.120  | 
                  Why?
                 |  | Risk Factors | 13  | 2025  | 10356  | 0.120  | 
                  Why?
                 |  | RNA, Catalytic | 2  | 1994  | 186  | 0.120  | 
                  Why?
                 |  | Trypanosoma cruzi | 1  | 1995  | 39  | 0.120  | 
                  Why?
                 |  | Photochemotherapy | 1  | 1995  | 37  | 0.120  | 
                  Why?
                 |  | Tuftsin | 3  | 1983  | 4  | 0.120  | 
                  Why?
                 |  | Host-Pathogen Interactions | 1  | 2018  | 367  | 0.120  | 
                  Why?
                 |  | Protein Kinase Inhibitors | 1  | 2021  | 920  | 0.120  | 
                  Why?
                 |  | Homeodomain Proteins | 1  | 1998  | 504  | 0.110  | 
                  Why?
                 |  | Cross-Sectional Studies | 7  | 2025  | 5427  | 0.110  | 
                  Why?
                 |  | Dermatologic Agents | 1  | 2015  | 69  | 0.110  | 
                  Why?
                 |  | Genes, Viral | 4  | 1992  | 88  | 0.110  | 
                  Why?
                 |  | Drug Therapy, Combination | 3  | 2018  | 1060  | 0.110  | 
                  Why?
                 |  | Receptors, Antigen, T-Cell, alpha-beta | 3  | 2022  | 337  | 0.110  | 
                  Why?
                 |  | Law Enforcement | 1  | 2014  | 40  | 0.110  | 
                  Why?
                 |  | Phenotype | 2  | 2019  | 3205  | 0.110  | 
                  Why?
                 |  | Nanoparticles | 2  | 2017  | 484  | 0.110  | 
                  Why?
                 |  | Crime | 1  | 2014  | 60  | 0.110  | 
                  Why?
                 |  | Cochlear Implants | 1  | 2015  | 110  | 0.110  | 
                  Why?
                 |  | Criminals | 1  | 2014  | 36  | 0.100  | 
                  Why?
                 |  | RNA, Viral | 4  | 1992  | 653  | 0.100  | 
                  Why?
                 |  | Graft Rejection | 2  | 2015  | 623  | 0.100  | 
                  Why?
                 |  | Withholding Treatment | 1  | 2013  | 76  | 0.100  | 
                  Why?
                 |  | Primary Cell Culture | 1  | 2013  | 172  | 0.100  | 
                  Why?
                 |  | Transglutaminases | 1  | 2013  | 156  | 0.100  | 
                  Why?
                 |  | Cytotoxicity, Immunologic | 2  | 2013  | 225  | 0.100  | 
                  Why?
                 |  | Adjuvants, Immunologic | 1  | 2014  | 226  | 0.100  | 
                  Why?
                 |  | Gene Expression | 2  | 2013  | 1505  | 0.100  | 
                  Why?
                 |  | Pancreatectomy | 1  | 2015  | 252  | 0.100  | 
                  Why?
                 |  | Adaptive Immunity | 1  | 2013  | 164  | 0.100  | 
                  Why?
                 |  | Reproducibility of Results | 3  | 2009  | 3292  | 0.100  | 
                  Why?
                 |  | Nucleic Acid Conformation | 3  | 1994  | 720  | 0.090  | 
                  Why?
                 |  | Communicable Diseases | 1  | 2014  | 160  | 0.090  | 
                  Why?
                 |  | Sensitivity and Specificity | 2  | 2009  | 1950  | 0.090  | 
                  Why?
                 |  | DNA, Viral | 1  | 1994  | 362  | 0.090  | 
                  Why?
                 |  | Diabetic Angiopathies | 2  | 2010  | 258  | 0.090  | 
                  Why?
                 |  | Receptors, Immunologic | 2  | 1983  | 223  | 0.090  | 
                  Why?
                 |  | Amino Acid Sequence | 9  | 2015  | 2146  | 0.090  | 
                  Why?
                 |  | RNA Phages | 2  | 1988  | 2  | 0.090  | 
                  Why?
                 |  | Flow Cytometry | 4  | 2019  | 1185  | 0.090  | 
                  Why?
                 |  | Proportional Hazards Models | 3  | 2021  | 1263  | 0.090  | 
                  Why?
                 |  | Thyroiditis | 1  | 1991  | 4  | 0.090  | 
                  Why?
                 |  | Alleles | 5  | 2011  | 891  | 0.090  | 
                  Why?
                 |  | Polymorphism, Genetic | 3  | 2010  | 658  | 0.090  | 
                  Why?
                 |  | Down-Regulation | 1  | 2014  | 658  | 0.090  | 
                  Why?
                 |  | Herpesviridae Infections | 1  | 2012  | 148  | 0.090  | 
                  Why?
                 |  | Lymphocyte Count | 3  | 2019  | 150  | 0.090  | 
                  Why?
                 |  | Epstein-Barr Virus Infections | 1  | 2012  | 99  | 0.090  | 
                  Why?
                 |  | Cells, Cultured | 7  | 2017  | 4206  | 0.090  | 
                  Why?
                 |  | Recombinant Proteins | 3  | 2018  | 1357  | 0.090  | 
                  Why?
                 |  | HLA-B Antigens | 1  | 2011  | 62  | 0.090  | 
                  Why?
                 |  | RNA, Double-Stranded | 2  | 1988  | 56  | 0.090  | 
                  Why?
                 |  | Organophosphorus Compounds | 1  | 2011  | 80  | 0.090  | 
                  Why?
                 |  | Cryopreservation | 1  | 2011  | 98  | 0.090  | 
                  Why?
                 |  | Glycine | 1  | 2011  | 175  | 0.090  | 
                  Why?
                 |  | Endocrine Cells | 1  | 2010  | 7  | 0.090  | 
                  Why?
                 |  | Interleukin-6 | 2  | 2012  | 778  | 0.090  | 
                  Why?
                 |  | Pilot Projects | 3  | 2021  | 1703  | 0.080  | 
                  Why?
                 |  | Transplantation Immunology | 1  | 1990  | 34  | 0.080  | 
                  Why?
                 |  | Molecular Sequence Data | 9  | 2015  | 2901  | 0.080  | 
                  Why?
                 |  | Drug Delivery Systems | 1  | 2013  | 363  | 0.080  | 
                  Why?
                 |  | Insulin, Long-Acting | 3  | 2004  | 63  | 0.080  | 
                  Why?
                 |  | HLA Antigens | 4  | 2022  | 237  | 0.080  | 
                  Why?
                 |  | Inflammation Mediators | 2  | 2010  | 514  | 0.080  | 
                  Why?
                 |  | Insulin Glargine | 3  | 2004  | 84  | 0.080  | 
                  Why?
                 |  | Single-Cell Analysis | 2  | 2025  | 309  | 0.080  | 
                  Why?
                 |  | Muromonab-CD3 | 1  | 2009  | 20  | 0.080  | 
                  Why?
                 |  | Genotype | 5  | 2015  | 1920  | 0.080  | 
                  Why?
                 |  | T-Lymphocytes, Cytotoxic | 2  | 2009  | 173  | 0.080  | 
                  Why?
                 |  | Enzyme-Linked Immunosorbent Assay | 4  | 2014  | 849  | 0.080  | 
                  Why?
                 |  | Adrenocorticotropic Hormone | 2  | 2012  | 142  | 0.080  | 
                  Why?
                 |  | Mental Health Services | 1  | 2014  | 415  | 0.080  | 
                  Why?
                 |  | Antigens | 3  | 2023  | 358  | 0.080  | 
                  Why?
                 |  | Receptors, Chemokine | 2  | 2007  | 47  | 0.080  | 
                  Why?
                 |  | Prognosis | 4  | 2021  | 4031  | 0.080  | 
                  Why?
                 |  | Interleukin-17 | 1  | 2009  | 120  | 0.080  | 
                  Why?
                 |  | Calcinosis | 1  | 2010  | 235  | 0.070  | 
                  Why?
                 |  | Vitamin D Deficiency | 1  | 2010  | 183  | 0.070  | 
                  Why?
                 |  | Bacteria | 1  | 2015  | 858  | 0.070  | 
                  Why?
                 |  | Immunodominant Epitopes | 2  | 2006  | 28  | 0.070  | 
                  Why?
                 |  | Insulin Infusion Systems | 2  | 2004  | 392  | 0.070  | 
                  Why?
                 |  | Remission Induction | 2  | 2018  | 287  | 0.070  | 
                  Why?
                 |  | Platelet Membrane Glycoprotein IIb | 1  | 2007  | 4  | 0.070  | 
                  Why?
                 |  | Enzyme-Linked Immunospot Assay | 3  | 2011  | 36  | 0.070  | 
                  Why?
                 |  | Homicide | 1  | 1988  | 66  | 0.070  | 
                  Why?
                 |  | Regression Analysis | 1  | 2010  | 1029  | 0.070  | 
                  Why?
                 |  | Hydrocortisone | 2  | 2012  | 318  | 0.070  | 
                  Why?
                 |  | Equipment Design | 1  | 2009  | 526  | 0.070  | 
                  Why?
                 |  | Consensus | 2  | 2023  | 685  | 0.070  | 
                  Why?
                 |  | Safety | 1  | 2009  | 342  | 0.070  | 
                  Why?
                 |  | Radioimmunoassay | 2  | 2017  | 174  | 0.070  | 
                  Why?
                 |  | Risk Assessment | 3  | 2025  | 3439  | 0.070  | 
                  Why?
                 |  | Case-Control Studies | 5  | 2016  | 3546  | 0.070  | 
                  Why?
                 |  | CD40 Antigens | 1  | 2007  | 89  | 0.070  | 
                  Why?
                 |  | Rituximab | 3  | 2013  | 178  | 0.060  | 
                  Why?
                 |  | Microsatellite Repeats | 2  | 2009  | 168  | 0.060  | 
                  Why?
                 |  | Receptors, Interleukin-7 | 1  | 2006  | 28  | 0.060  | 
                  Why?
                 |  | Disease Models, Animal | 2  | 2009  | 4295  | 0.060  | 
                  Why?
                 |  | Killer Cells, Natural | 2  | 2016  | 446  | 0.060  | 
                  Why?
                 |  | Bacteriophages | 1  | 1988  | 95  | 0.060  | 
                  Why?
                 |  | CD4 Lymphocyte Count | 3  | 2015  | 270  | 0.060  | 
                  Why?
                 |  | Hybridomas | 2  | 2004  | 237  | 0.060  | 
                  Why?
                 |  | Mutation | 5  | 2015  | 3964  | 0.060  | 
                  Why?
                 |  | Atherosclerosis | 1  | 2010  | 415  | 0.060  | 
                  Why?
                 |  | Isoenzymes | 2  | 2004  | 305  | 0.060  | 
                  Why?
                 |  | Infant | 5  | 2024  | 9467  | 0.060  | 
                  Why?
                 |  | Diabetic Retinopathy | 2  | 2005  | 189  | 0.060  | 
                  Why?
                 |  | Proteins | 2  | 2018  | 1012  | 0.060  | 
                  Why?
                 |  | Disease Susceptibility | 2  | 2019  | 344  | 0.060  | 
                  Why?
                 |  | Protein Tyrosine Phosphatases | 2  | 2004  | 171  | 0.060  | 
                  Why?
                 |  | Gene Frequency | 3  | 2016  | 521  | 0.060  | 
                  Why?
                 |  | Mental Disorders | 1  | 2014  | 1083  | 0.060  | 
                  Why?
                 |  | Chemokines, CXC | 1  | 2005  | 70  | 0.060  | 
                  Why?
                 |  | Signal Transduction | 3  | 2019  | 5096  | 0.060  | 
                  Why?
                 |  | Risk | 3  | 2019  | 905  | 0.060  | 
                  Why?
                 |  | Urban Population | 1  | 1988  | 475  | 0.060  | 
                  Why?
                 |  | Prevalence | 3  | 2024  | 2719  | 0.060  | 
                  Why?
                 |  | Acetamides | 1  | 2005  | 36  | 0.060  | 
                  Why?
                 |  | Major Histocompatibility Complex | 2  | 2002  | 231  | 0.060  | 
                  Why?
                 |  | Exanthema | 2  | 2019  | 77  | 0.060  | 
                  Why?
                 |  | Receptors, Antigen, B-Cell | 1  | 2025  | 130  | 0.060  | 
                  Why?
                 |  | Blood Coagulation Factors | 1  | 1984  | 54  | 0.060  | 
                  Why?
                 |  | Coronary Artery Disease | 1  | 2010  | 703  | 0.050  | 
                  Why?
                 |  | Immunophenotyping | 2  | 2018  | 321  | 0.050  | 
                  Why?
                 |  | Immunoglobulin Fragments | 1  | 1983  | 12  | 0.050  | 
                  Why?
                 |  | Feces | 2  | 2018  | 479  | 0.050  | 
                  Why?
                 |  | Base Sequence | 6  | 1994  | 2180  | 0.050  | 
                  Why?
                 |  | Niacinamide | 1  | 2004  | 79  | 0.050  | 
                  Why?
                 |  | Genes, MHC Class II | 2  | 2002  | 74  | 0.050  | 
                  Why?
                 |  | Placebos | 2  | 2013  | 207  | 0.050  | 
                  Why?
                 |  | Leukocytes, Mononuclear | 2  | 2019  | 558  | 0.050  | 
                  Why?
                 |  | Age Factors | 3  | 2017  | 3301  | 0.050  | 
                  Why?
                 |  | Intercellular Signaling Peptides and Proteins | 1  | 2005  | 379  | 0.050  | 
                  Why?
                 |  | Immunoassay | 1  | 2003  | 114  | 0.050  | 
                  Why?
                 |  | Genetic Association Studies | 1  | 2025  | 377  | 0.050  | 
                  Why?
                 |  | Cell Survival | 2  | 2019  | 1122  | 0.050  | 
                  Why?
                 |  | Tissue Donors | 1  | 2006  | 417  | 0.050  | 
                  Why?
                 |  | Interleukin-4 | 2  | 2002  | 217  | 0.050  | 
                  Why?
                 |  | Antigens, CD1 | 1  | 2002  | 59  | 0.050  | 
                  Why?
                 |  | Mice, Knockout | 1  | 2009  | 3020  | 0.050  | 
                  Why?
                 |  | Siblings | 2  | 2018  | 228  | 0.050  | 
                  Why?
                 |  | Receptors, CXCR3 | 2  | 2016  | 16  | 0.050  | 
                  Why?
                 |  | Antibody Affinity | 2  | 2016  | 60  | 0.050  | 
                  Why?
                 |  | Cloning, Molecular | 3  | 2014  | 536  | 0.050  | 
                  Why?
                 |  | Cell Differentiation | 1  | 2009  | 1979  | 0.050  | 
                  Why?
                 |  | Canada | 2  | 2014  | 421  | 0.050  | 
                  Why?
                 |  | Denmark | 2  | 2014  | 46  | 0.050  | 
                  Why?
                 |  | Preconception Care | 1  | 2002  | 43  | 0.050  | 
                  Why?
                 |  | Diseases in Twins | 2  | 2018  | 175  | 0.050  | 
                  Why?
                 |  | Labor, Obstetric | 1  | 2002  | 61  | 0.050  | 
                  Why?
                 |  | Pyrimidines | 1  | 2005  | 472  | 0.050  | 
                  Why?
                 |  | Cell Proliferation | 2  | 2009  | 2482  | 0.050  | 
                  Why?
                 |  | Reference Values | 3  | 2009  | 821  | 0.040  | 
                  Why?
                 |  | Proto-Oncogene Proteins c-sis | 1  | 2001  | 37  | 0.040  | 
                  Why?
                 |  | Pancreas | 2  | 2018  | 328  | 0.040  | 
                  Why?
                 |  | Algorithms | 1  | 2008  | 1702  | 0.040  | 
                  Why?
                 |  | Administration, Topical | 1  | 2001  | 149  | 0.040  | 
                  Why?
                 |  | Pregnancy Outcome | 1  | 2003  | 413  | 0.040  | 
                  Why?
                 |  | Venoms | 1  | 2020  | 29  | 0.040  | 
                  Why?
                 |  | Vitamin D | 1  | 2004  | 393  | 0.040  | 
                  Why?
                 |  | DNA | 4  | 1994  | 1460  | 0.040  | 
                  Why?
                 |  | Rats, Inbred BB | 2  | 1991  | 6  | 0.040  | 
                  Why?
                 |  | Bacterial Proteins | 2  | 2018  | 889  | 0.040  | 
                  Why?
                 |  | Kinetics | 4  | 1994  | 1679  | 0.040  | 
                  Why?
                 |  | Diagnostic Techniques, Endocrine | 1  | 2020  | 14  | 0.040  | 
                  Why?
                 |  | HLA-DR2 Antigen | 1  | 1999  | 7  | 0.040  | 
                  Why?
                 |  | Dose-Response Relationship, Immunologic | 1  | 2019  | 82  | 0.040  | 
                  Why?
                 |  | Antibodies, Heterophile | 1  | 1999  | 14  | 0.040  | 
                  Why?
                 |  | Membrane Proteins | 2  | 2004  | 1167  | 0.040  | 
                  Why?
                 |  | HLA-DRB1 Chains | 3  | 2009  | 112  | 0.040  | 
                  Why?
                 |  | Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 3  | 2007  | 48  | 0.040  | 
                  Why?
                 |  | Interleukin-7 | 1  | 2019  | 62  | 0.040  | 
                  Why?
                 |  | ROC Curve | 1  | 2021  | 547  | 0.040  | 
                  Why?
                 |  | Hemorrhage | 1  | 1984  | 723  | 0.040  | 
                  Why?
                 |  | Lymphocytes | 1  | 2002  | 395  | 0.040  | 
                  Why?
                 |  | HLA-A Antigens | 2  | 2011  | 56  | 0.040  | 
                  Why?
                 |  | CD4-CD8 Ratio | 1  | 2019  | 22  | 0.040  | 
                  Why?
                 |  | Mice, Inbred BALB C | 4  | 2011  | 1271  | 0.040  | 
                  Why?
                 |  | Leg | 1  | 2001  | 223  | 0.040  | 
                  Why?
                 |  | Evidence-Based Medicine | 1  | 2023  | 746  | 0.040  | 
                  Why?
                 |  | Lymphopenia | 1  | 2019  | 61  | 0.040  | 
                  Why?
                 |  | Methylation | 1  | 2019  | 237  | 0.040  | 
                  Why?
                 |  | Databases, Factual | 1  | 2004  | 1351  | 0.040  | 
                  Why?
                 |  | High-Throughput Nucleotide Sequencing | 1  | 2022  | 538  | 0.040  | 
                  Why?
                 |  | Postpartum Period | 1  | 2002  | 341  | 0.040  | 
                  Why?
                 |  | Prospective Studies | 4  | 2016  | 7598  | 0.040  | 
                  Why?
                 |  | Seroconversion | 1  | 2018  | 46  | 0.040  | 
                  Why?
                 |  | Insulin Lispro | 3  | 2004  | 39  | 0.040  | 
                  Why?
                 |  | Meals | 1  | 2020  | 122  | 0.040  | 
                  Why?
                 |  | Macrophages | 2  | 1983  | 1548  | 0.040  | 
                  Why?
                 |  | Mucosal-Associated Invariant T Cells | 1  | 2018  | 37  | 0.040  | 
                  Why?
                 |  | Therapies, Investigational | 1  | 2018  | 17  | 0.040  | 
                  Why?
                 |  | Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1  | 2018  | 11  | 0.040  | 
                  Why?
                 |  | B7-2 Antigen | 1  | 2017  | 27  | 0.040  | 
                  Why?
                 |  | Seroepidemiologic Studies | 1  | 2018  | 163  | 0.040  | 
                  Why?
                 |  | Wound Healing | 1  | 2001  | 327  | 0.040  | 
                  Why?
                 |  | Ikaros Transcription Factor | 1  | 2018  | 24  | 0.040  | 
                  Why?
                 |  | Glucose | 1  | 2023  | 1018  | 0.040  | 
                  Why?
                 |  | Colorado | 2  | 2024  | 4521  | 0.040  | 
                  Why?
                 |  | Cell Death | 1  | 2019  | 370  | 0.040  | 
                  Why?
                 |  | Aged | 7  | 2014  | 23798  | 0.030  | 
                  Why?
                 |  | Capsid | 2  | 1988  | 93  | 0.030  | 
                  Why?
                 |  | Patient Care Planning | 1  | 2018  | 155  | 0.030  | 
                  Why?
                 |  | Mice, Transgenic | 2  | 2018  | 2182  | 0.030  | 
                  Why?
                 |  | Drug Discovery | 1  | 2018  | 141  | 0.030  | 
                  Why?
                 |  | Rats | 3  | 1991  | 5676  | 0.030  | 
                  Why?
                 |  | Clone Cells | 3  | 2004  | 266  | 0.030  | 
                  Why?
                 |  | Controlled Clinical Trials as Topic | 1  | 2016  | 28  | 0.030  | 
                  Why?
                 |  | Structure-Activity Relationship | 2  | 2011  | 586  | 0.030  | 
                  Why?
                 |  | Antigens, CD | 2  | 2014  | 524  | 0.030  | 
                  Why?
                 |  | Genetic Markers | 1  | 1998  | 345  | 0.030  | 
                  Why?
                 |  | United States | 4  | 2015  | 14696  | 0.030  | 
                  Why?
                 |  | Twins | 1  | 2018  | 253  | 0.030  | 
                  Why?
                 |  | CD56 Antigen | 1  | 2016  | 36  | 0.030  | 
                  Why?
                 |  | Luminescent Measurements | 1  | 2017  | 76  | 0.030  | 
                  Why?
                 |  | Gene Expression Regulation | 3  | 2014  | 2615  | 0.030  | 
                  Why?
                 |  | Influenza A virus | 1  | 1997  | 109  | 0.030  | 
                  Why?
                 |  | Receptors, IgG | 1  | 2016  | 75  | 0.030  | 
                  Why?
                 |  | HLA-DQ beta-Chains | 2  | 2009  | 63  | 0.030  | 
                  Why?
                 |  | Leukocyte Common Antigens | 2  | 2007  | 87  | 0.030  | 
                  Why?
                 |  | Retrospective Studies | 4  | 2025  | 15628  | 0.030  | 
                  Why?
                 |  | Environment | 1  | 2018  | 362  | 0.030  | 
                  Why?
                 |  | Cell Count | 1  | 2017  | 321  | 0.030  | 
                  Why?
                 |  | Somalia | 1  | 2016  | 10  | 0.030  | 
                  Why?
                 |  | Antibody Specificity | 2  | 2007  | 189  | 0.030  | 
                  Why?
                 |  | Isoindoles | 1  | 1995  | 5  | 0.030  | 
                  Why?
                 |  | Forecasting | 1  | 1998  | 386  | 0.030  | 
                  Why?
                 |  | Parasitemia | 1  | 1995  | 13  | 0.030  | 
                  Why?
                 |  | Predictive Value of Tests | 2  | 2012  | 2039  | 0.030  | 
                  Why?
                 |  | Orphan Drug Production | 1  | 2015  | 5  | 0.030  | 
                  Why?
                 |  | Organ Specificity | 2  | 2007  | 304  | 0.030  | 
                  Why?
                 |  | Radiation-Sensitizing Agents | 1  | 1995  | 43  | 0.030  | 
                  Why?
                 |  | Coloring Agents | 1  | 1995  | 86  | 0.030  | 
                  Why?
                 |  | Cities | 1  | 2016  | 132  | 0.030  | 
                  Why?
                 |  | Minnesota | 1  | 2016  | 161  | 0.030  | 
                  Why?
                 |  | Transfusion Reaction | 1  | 1995  | 46  | 0.030  | 
                  Why?
                 |  | Cohort Studies | 3  | 2015  | 5730  | 0.030  | 
                  Why?
                 |  | Chagas Disease | 1  | 1995  | 43  | 0.030  | 
                  Why?
                 |  | Immunity, Humoral | 1  | 2016  | 118  | 0.030  | 
                  Why?
                 |  | Intestines | 1  | 2018  | 359  | 0.030  | 
                  Why?
                 |  | Ethics, Medical | 1  | 2015  | 81  | 0.030  | 
                  Why?
                 |  | Immunity, Active | 1  | 2014  | 10  | 0.030  | 
                  Why?
                 |  | Sequence Homology, Amino Acid | 1  | 2015  | 387  | 0.030  | 
                  Why?
                 |  | Early Diagnosis | 1  | 2015  | 244  | 0.030  | 
                  Why?
                 |  | Transcription, Genetic | 4  | 1994  | 1458  | 0.030  | 
                  Why?
                 |  | Immunity, Innate | 2  | 2009  | 832  | 0.030  | 
                  Why?
                 |  | Proline | 1  | 1994  | 80  | 0.030  | 
                  Why?
                 |  | Opportunistic Infections | 1  | 2014  | 47  | 0.030  | 
                  Why?
                 |  | Immunoglobulins | 1  | 2014  | 171  | 0.030  | 
                  Why?
                 |  | Transplantation, Autologous | 1  | 2015  | 238  | 0.030  | 
                  Why?
                 |  | Single-Blind Method | 1  | 2014  | 288  | 0.030  | 
                  Why?
                 |  | In Vitro Techniques | 1  | 1995  | 1108  | 0.030  | 
                  Why?
                 |  | Protein Structure, Secondary | 1  | 1994  | 373  | 0.030  | 
                  Why?
                 |  | Drug Combinations | 1  | 2014  | 344  | 0.030  | 
                  Why?
                 |  | Prosthesis Design | 1  | 2015  | 309  | 0.030  | 
                  Why?
                 |  | Sequence Deletion | 1  | 1994  | 183  | 0.030  | 
                  Why?
                 |  | Europe | 1  | 2014  | 414  | 0.030  | 
                  Why?
                 |  | Mutagenesis | 1  | 1994  | 182  | 0.030  | 
                  Why?
                 |  | Cytotoxicity Tests, Immunologic | 1  | 2013  | 41  | 0.030  | 
                  Why?
                 |  | Cost of Illness | 1  | 2015  | 304  | 0.030  | 
                  Why?
                 |  | Formamides | 1  | 1992  | 6  | 0.030  | 
                  Why?
                 |  | Interleukin-10 | 1  | 2015  | 302  | 0.030  | 
                  Why?
                 |  | Virus Replication | 3  | 1997  | 480  | 0.020  | 
                  Why?
                 |  | Herpesviridae | 1  | 2012  | 23  | 0.020  | 
                  Why?
                 |  | Escherichia coli Proteins | 1  | 1994  | 195  | 0.020  | 
                  Why?
                 |  | RNA, Ribosomal, 16S | 1  | 2015  | 544  | 0.020  | 
                  Why?
                 |  | Body Mass Index | 1  | 2021  | 2369  | 0.020  | 
                  Why?
                 |  | Immunocompromised Host | 1  | 2014  | 203  | 0.020  | 
                  Why?
                 |  | Pregnancy | 2  | 2003  | 6745  | 0.020  | 
                  Why?
                 |  | Renin | 1  | 2012  | 34  | 0.020  | 
                  Why?
                 |  | Interleukins | 1  | 2014  | 251  | 0.020  | 
                  Why?
                 |  | Indoles | 1  | 1995  | 415  | 0.020  | 
                  Why?
                 |  | Postprandial Period | 1  | 2013  | 105  | 0.020  | 
                  Why?
                 |  | Influenza Vaccines | 1  | 1997  | 551  | 0.020  | 
                  Why?
                 |  | Lymph Nodes | 2  | 2006  | 493  | 0.020  | 
                  Why?
                 |  | RNA, Antisense | 1  | 1992  | 17  | 0.020  | 
                  Why?
                 |  | Virus Activation | 1  | 2012  | 89  | 0.020  | 
                  Why?
                 |  | Graft Survival | 1  | 2015  | 540  | 0.020  | 
                  Why?
                 |  | Herpesvirus 4, Human | 1  | 2012  | 167  | 0.020  | 
                  Why?
                 |  | HLA-B15 Antigen | 1  | 2011  | 13  | 0.020  | 
                  Why?
                 |  | Ligands | 2  | 2005  | 665  | 0.020  | 
                  Why?
                 |  | Proteomics | 1  | 2018  | 1113  | 0.020  | 
                  Why?
                 |  | Sample Size | 1  | 2011  | 118  | 0.020  | 
                  Why?
                 |  | Cognition Disorders | 1  | 2015  | 517  | 0.020  | 
                  Why?
                 |  | Societies, Medical | 1  | 2015  | 820  | 0.020  | 
                  Why?
                 |  | Thallium Radioisotopes | 1  | 1991  | 8  | 0.020  | 
                  Why?
                 |  | Phagocytosis | 2  | 1983  | 379  | 0.020  | 
                  Why?
                 |  | Receptors, Cell Surface | 2  | 1983  | 391  | 0.020  | 
                  Why?
                 |  | Vitamin D-Binding Protein | 1  | 2010  | 15  | 0.020  | 
                  Why?
                 |  | RNA Splicing | 1  | 1992  | 268  | 0.020  | 
                  Why?
                 |  | Small Molecule Libraries | 1  | 2011  | 96  | 0.020  | 
                  Why?
                 |  | HLA-B8 Antigen | 1  | 2010  | 14  | 0.020  | 
                  Why?
                 |  | Chronic Disease | 1  | 2017  | 1790  | 0.020  | 
                  Why?
                 |  | Isoantigens | 1  | 1990  | 15  | 0.020  | 
                  Why?
                 |  | Receptors, Calcitriol | 1  | 2010  | 55  | 0.020  | 
                  Why?
                 |  | Polymerase Chain Reaction | 2  | 2009  | 1061  | 0.020  | 
                  Why?
                 |  | Amino Acid Substitution | 2  | 2002  | 309  | 0.020  | 
                  Why?
                 |  | Rats, Inbred Strains | 1  | 1990  | 369  | 0.020  | 
                  Why?
                 |  | Spleen | 3  | 2002  | 516  | 0.020  | 
                  Why?
                 |  | Linkage Disequilibrium | 1  | 2010  | 268  | 0.020  | 
                  Why?
                 |  | Chemokines | 1  | 2010  | 229  | 0.020  | 
                  Why?
                 |  | DNA Mutational Analysis | 1  | 2010  | 401  | 0.020  | 
                  Why?
                 |  | Homozygote | 1  | 2009  | 203  | 0.020  | 
                  Why?
                 |  | Pedigree | 1  | 2010  | 514  | 0.020  | 
                  Why?
                 |  | Immunoblotting | 1  | 2009  | 307  | 0.020  | 
                  Why?
                 |  | Transplantation, Homologous | 1  | 1990  | 416  | 0.020  | 
                  Why?
                 |  | Coculture Techniques | 1  | 2009  | 240  | 0.020  | 
                  Why?
                 |  | Longitudinal Studies | 1  | 2016  | 2857  | 0.020  | 
                  Why?
                 |  | Nausea | 1  | 2009  | 115  | 0.020  | 
                  Why?
                 |  | Logistic Models | 1  | 2014  | 2064  | 0.020  | 
                  Why?
                 |  | Vomiting | 1  | 2009  | 133  | 0.020  | 
                  Why?
                 |  | Interferon-alpha | 1  | 2009  | 198  | 0.020  | 
                  Why?
                 |  | Coronary Disease | 1  | 1991  | 385  | 0.020  | 
                  Why?
                 |  | Immunoglobulin M | 1  | 2009  | 288  | 0.020  | 
                  Why?
                 |  | Pseudomonas | 1  | 1988  | 31  | 0.020  | 
                  Why?
                 |  | Genetic Complementation Test | 1  | 1988  | 66  | 0.020  | 
                  Why?
                 |  | Genetic Vectors | 1  | 2009  | 322  | 0.020  | 
                  Why?
                 |  | Mice, Inbred Strains | 1  | 1988  | 413  | 0.020  | 
                  Why?
                 |  | Codon | 1  | 1988  | 90  | 0.020  | 
                  Why?
                 |  | Exercise Test | 1  | 1991  | 621  | 0.020  | 
                  Why?
                 |  | DNA Methylation | 1  | 2013  | 644  | 0.020  | 
                  Why?
                 |  | Cell Line | 2  | 2004  | 2852  | 0.020  | 
                  Why?
                 |  | Fever | 1  | 2009  | 307  | 0.020  | 
                  Why?
                 |  | Immunotherapy, Adoptive | 1  | 1991  | 324  | 0.020  | 
                  Why?
                 |  | Up-Regulation | 1  | 2010  | 846  | 0.020  | 
                  Why?
                 |  | Microscopy, Electron | 1  | 1988  | 434  | 0.020  | 
                  Why?
                 |  | DNA-Binding Proteins | 1  | 1994  | 1507  | 0.020  | 
                  Why?
                 |  | Morphogenesis | 1  | 1988  | 166  | 0.020  | 
                  Why?
                 |  | Gastrointestinal Diseases | 1  | 2009  | 210  | 0.020  | 
                  Why?
                 |  | Interleukin-2 Receptor alpha Subunit | 1  | 2007  | 84  | 0.020  | 
                  Why?
                 |  | Antisocial Personality Disorder | 1  | 1988  | 170  | 0.020  | 
                  Why?
                 |  | Age Distribution | 1  | 2007  | 391  | 0.020  | 
                  Why?
                 |  | NF-kappa B | 1  | 2010  | 694  | 0.020  | 
                  Why?
                 |  | Chromogranins | 1  | 2006  | 15  | 0.020  | 
                  Why?
                 |  | Models, Molecular | 1  | 2011  | 1586  | 0.020  | 
                  Why?
                 |  | Social Environment | 1  | 1988  | 305  | 0.020  | 
                  Why?
                 |  | Phosphorylation | 1  | 2010  | 1762  | 0.020  | 
                  Why?
                 |  | Mice, Inbred C3H | 2  | 1983  | 272  | 0.020  | 
                  Why?
                 |  | Psychotic Disorders | 1  | 1988  | 167  | 0.020  | 
                  Why?
                 |  | Hemodynamics | 1  | 1991  | 1114  | 0.020  | 
                  Why?
                 |  | Oligonucleotide Array Sequence Analysis | 1  | 2007  | 765  | 0.010  | 
                  Why?
                 |  | Chemokine CXCL11 | 1  | 2005  | 3  | 0.010  | 
                  Why?
                 |  | Keratins | 1  | 2006  | 173  | 0.010  | 
                  Why?
                 |  | Guanosine 5'-O-(3-Thiotriphosphate) | 1  | 2005  | 15  | 0.010  | 
                  Why?
                 |  | Iodide Peroxidase | 1  | 2005  | 28  | 0.010  | 
                  Why?
                 |  | Glucagon | 1  | 2006  | 109  | 0.010  | 
                  Why?
                 |  | Thyroglobulin | 1  | 2005  | 27  | 0.010  | 
                  Why?
                 |  | Alprostadil | 1  | 2005  | 32  | 0.010  | 
                  Why?
                 |  | Chemokine CXCL9 | 1  | 2005  | 27  | 0.010  | 
                  Why?
                 |  | Mice, Inbred C57BL | 2  | 2011  | 5792  | 0.010  | 
                  Why?
                 |  | Chemokine CXCL10 | 1  | 2005  | 39  | 0.010  | 
                  Why?
                 |  | Lupus Coagulation Inhibitor | 1  | 1984  | 7  | 0.010  | 
                  Why?
                 |  | Antigenic Variation | 1  | 2004  | 10  | 0.010  | 
                  Why?
                 |  | Fathers | 1  | 2005  | 50  | 0.010  | 
                  Why?
                 |  | Dinoprostone | 1  | 2005  | 191  | 0.010  | 
                  Why?
                 |  | Interpersonal Relations | 1  | 1988  | 411  | 0.010  | 
                  Why?
                 |  | Mice, Inbred CBA | 1  | 2004  | 54  | 0.010  | 
                  Why?
                 |  | Tetanus Toxin | 1  | 2003  | 6  | 0.010  | 
                  Why?
                 |  | Infusion Pumps, Implantable | 1  | 2004  | 25  | 0.010  | 
                  Why?
                 |  | Chaperonin 60 | 1  | 2003  | 14  | 0.010  | 
                  Why?
                 |  | Insulin Aspart | 1  | 2004  | 27  | 0.010  | 
                  Why?
                 |  | Injections, Subcutaneous | 1  | 2004  | 154  | 0.010  | 
                  Why?
                 |  | Homeostasis | 1  | 2007  | 622  | 0.010  | 
                  Why?
                 |  | Quality of Life | 1  | 2015  | 2870  | 0.010  | 
                  Why?
                 |  | Indicators and Reagents | 1  | 1983  | 109  | 0.010  | 
                  Why?
                 |  | Escherichia coli | 1  | 1988  | 815  | 0.010  | 
                  Why?
                 |  | Fibrosis | 1  | 2006  | 552  | 0.010  | 
                  Why?
                 |  | Postoperative Complications | 1  | 2015  | 2641  | 0.010  | 
                  Why?
                 |  | Biological Assay | 1  | 1983  | 123  | 0.010  | 
                  Why?
                 |  | Fetal Macrosomia | 1  | 2003  | 62  | 0.010  | 
                  Why?
                 |  | Binding, Competitive | 1  | 1983  | 211  | 0.010  | 
                  Why?
                 |  | Models, Biological | 1  | 1990  | 1775  | 0.010  | 
                  Why?
                 |  | Antigens, CD1d | 1  | 2002  | 68  | 0.010  | 
                  Why?
                 |  | Congenital Abnormalities | 1  | 2003  | 88  | 0.010  | 
                  Why?
                 |  | C-Reactive Protein | 1  | 2005  | 411  | 0.010  | 
                  Why?
                 |  | Drug Administration Schedule | 1  | 2004  | 784  | 0.010  | 
                  Why?
                 |  | Interleukin-2 | 1  | 2004  | 456  | 0.010  | 
                  Why?
                 |  | Antigens, Surface | 1  | 2002  | 154  | 0.010  | 
                  Why?
                 |  | Antigens, Differentiation | 1  | 2002  | 83  | 0.010  | 
                  Why?
                 |  | Cell Division | 1  | 2004  | 795  | 0.010  | 
                  Why?
                 |  | Insulin Resistance | 1  | 2010  | 1198  | 0.010  | 
                  Why?
                 |  | Albuminuria | 1  | 2003  | 185  | 0.010  | 
                  Why?
                 |  | Sex Factors | 1  | 1988  | 2074  | 0.010  | 
                  Why?
                 |  | Celiac Disease | 1  | 2005  | 293  | 0.010  | 
                  Why?
                 |  | CTLA-4 Antigen | 1  | 2002  | 99  | 0.010  | 
                  Why?
                 |  | Temperature | 2  | 1997  | 680  | 0.010  | 
                  Why?
                 |  | Immunohistochemistry | 1  | 2006  | 1740  | 0.010  | 
                  Why?
                 |  | Multivariate Analysis | 1  | 2005  | 1524  | 0.010  | 
                  Why?
                 |  | Alcoholism | 1  | 1988  | 805  | 0.010  | 
                  Why?
                 |  | HLA-DQ alpha-Chains | 1  | 1999  | 16  | 0.010  | 
                  Why?
                 |  | Gestational Age | 1  | 2003  | 903  | 0.010  | 
                  Why?
                 |  | Birth Weight | 1  | 2003  | 516  | 0.010  | 
                  Why?
                 |  | Glutamine | 1  | 2000  | 104  | 0.010  | 
                  Why?
                 |  | Alanine | 1  | 2000  | 153  | 0.010  | 
                  Why?
                 |  | Substance-Related Disorders | 1  | 1988  | 1079  | 0.010  | 
                  Why?
                 |  | Aging | 2  | 2007  | 1866  | 0.010  | 
                  Why?
                 |  | Mothers | 1  | 2005  | 752  | 0.010  | 
                  Why?
                 |  | Incidence | 1  | 2005  | 2792  | 0.010  | 
                  Why?
                 |  | Mesocricetus | 1  | 1997  | 39  | 0.010  | 
                  Why?
                 |  | Cricetinae | 1  | 1997  | 288  | 0.010  | 
                  Why?
                 |  | Chickens | 1  | 1997  | 192  | 0.010  | 
                  Why?
                 |  | Cell Line, Tumor | 1  | 2005  | 3420  | 0.010  | 
                  Why?
                 |  | Vaccines, Attenuated | 1  | 1997  | 131  | 0.010  | 
                  Why?
                 |  | Trifluoroethanol | 1  | 1994  | 1  | 0.010  | 
                  Why?
                 |  | Polydeoxyribonucleotides | 1  | 1994  | 14  | 0.010  | 
                  Why?
                 |  | Electrophoresis, Agar Gel | 1  | 1994  | 26  | 0.010  | 
                  Why?
                 |  | Sodium Dodecyl Sulfate | 1  | 1994  | 26  | 0.010  | 
                  Why?
                 |  | Transfection | 1  | 1997  | 948  | 0.010  | 
                  Why?
                 |  | Survival Rate | 1  | 1999  | 1980  | 0.010  | 
                  Why?
                 |  | Circular Dichroism | 1  | 1994  | 151  | 0.010  | 
                  Why?
                 |  | DNA, Single-Stranded | 1  | 1994  | 118  | 0.010  | 
                  Why?
                 |  | Electrophoresis, Polyacrylamide Gel | 1  | 1992  | 346  | 0.010  | 
                  Why?
                 |  | Genome, Viral | 1  | 1992  | 144  | 0.010  | 
                  Why?
                 |  | Radionuclide Imaging | 1  | 1991  | 119  | 0.010  | 
                  Why?
                 |  | Computer Simulation | 1  | 1994  | 986  | 0.010  | 
                  Why?
                 |  | DNA-Directed RNA Polymerases | 1  | 1988  | 57  | 0.000  | 
                  Why?
                 |  | Neoplasms | 1  | 1983  | 2666  | 0.000  | 
                  Why?
                 |  | Lethal Dose 50 | 1  | 1983  | 15  | 0.000  | 
                  Why?
                 |  | Fibrosarcoma | 1  | 1983  | 22  | 0.000  | 
                  Why?
                 |  | Leukocytosis | 1  | 1983  | 31  | 0.000  | 
                  Why?
                 |  | Neoplasm Transplantation | 1  | 1983  | 256  | 0.000  | 
                  Why?
                 |  | Leukocyte Count | 1  | 1983  | 331  | 0.000  | 
                  Why?
                 |  | Dogs | 1  | 1983  | 411  | 0.000  | 
                  Why?
                 |  | Hypertension | 1  | 1991  | 1293  | 0.000  | 
                  Why?
                 |  
  
																				
                                                                            
																		
																	 
																 
															 | 
		
																
																	
																		
																			
																					
    Gottlieb's Networks
 
Click the "See All" links for more information and interactive visualizations!
 
																				
																					Concepts   Derived automatically from this person's publications. _ 
																				
																					Co-Authors   People in Profiles who have published with this person. _ 
																				
																					Similar People   People who share similar concepts with this person. _ 
																				
																					
        
            
                Same Department  
                     
                
             
            
				People who are also in this person's primary department.
			 
                 
        
    
																				
																					Physical Neighbors   People whose addresses are nearby this person. _ 
																				
																		
																	 
																 
															 |